While combination VEGF blockade and checkpoint inhibitors have shown activity in ASPS[4] and osteosarcoma[37], outcomes in other soft tissue sarcomas have not been convincingly different from what could be expected from checkpoint inhibitor therapy alone. Here, VEGFA is linked to soft tissue sarcoma.